Head-To-Head Analysis: ChromaDex Corporation (CDXC) vs. Advaxis (ADXS)
ChromaDex Corporation (NASDAQ: CDXC) and Advaxis (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Insider and Institutional Ownership
8.0% of ChromaDex Corporation shares are owned by institutional investors. Comparatively, 47.9% of Advaxis shares are owned by institutional investors. 11.6% of ChromaDex Corporation shares are owned by company insiders. Comparatively, 7.2% of Advaxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
ChromaDex Corporation has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Advaxis has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
Valuation and Earnings
This table compares ChromaDex Corporation and Advaxis’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|ChromaDex Corporation||$26.81 million||11.94||-$2.92 million||($0.14)||-47.43|
|Advaxis||$3.99 million||33.35||-$73.55 million||($2.29)||-1.41|
ChromaDex Corporation has higher revenue and earnings than Advaxis. ChromaDex Corporation is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and recommmendations for ChromaDex Corporation and Advaxis, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ChromaDex Corporation currently has a consensus target price of $6.33, indicating a potential downside of 4.62%. Advaxis has a consensus target price of $21.00, indicating a potential upside of 548.15%. Given Advaxis’ higher possible upside, analysts clearly believe Advaxis is more favorable than ChromaDex Corporation.
This table compares ChromaDex Corporation and Advaxis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ChromaDex Corporation beats Advaxis on 8 of the 12 factors compared between the two stocks.
ChromaDex Corporation Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Advaxis Company Profile
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.